- Home
- DYAI vs IGC Comparison
DYAI vs IGC Comparison
Compare DYAI & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DYAI | IGC |
|---|---|---|
| Founded | 1979 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.8M | 28.5M |
| IPO Year | 2003 | 2005 |
Fundamental Metrics
Financial Performance| Metric | DYAI | IGC |
|---|---|---|
| Price | $0.83 | $0.28 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $3.00 | ★ $4.25 |
| AVG Volume (30 Days) | 53.0K | ★ 301.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 59.09 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,495,389.00 | $1,271,000.00 |
| Revenue This Year | $12.52 | $3.54 |
| Revenue Next Year | $92.04 | $15.12 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 20.58 | N/A |
| 52 Week Low | $0.71 | $0.24 |
| 52 Week High | $1.55 | $0.50 |
Technical Indicators
Market Signals| Indicator | DYAI | IGC |
|---|---|---|
| Relative Strength Index (RSI) | 50.51 | 55.39 |
| Support Level | $0.73 | N/A |
| Resistance Level | $0.84 | $0.32 |
| Average True Range (ATR) | 0.06 | 0.02 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 67.30 | 53.62 |
Price Performance
Historical ComparisonAbout DYAI Dyadic International Inc.
Dyadic International Inc is a worldwide biotechnology platform company. It has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.